Could a safer drug dose transform recovery after stem cell transplants?
NCT ID NCT07193420
Summary
This study aims to see if using a lower dose of a powerful drug called cyclophosphamide after a stem cell transplant is just as effective as the standard higher dose. It will involve 180 adults with blood cancers who are receiving a transplant from a half-matched donor. The main goal is to see if the lower dose helps patients survive without severe complications like graft-versus-host disease, cancer relapse, or serious drug side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Saint Antoine Hospital - Hematology Department
Paris, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.